Updates in Oncology Pharmacy: Adjuvant pertuzumab & nilotinib discontinuation (CML)
Jan 5, 2018
20:20
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
Review of recent FDA action re: oncology pharmacy including review of the APHINITIY trial and pertuzumab's subsequent approval in the adjuvant setting. Also, the nilotinib label change allowing for discontinuation in CML patients is discussed.